ACP1 and prostate cancer: In line with the above results, we found that LMW‐PTP silencing (Figure S4A and B) enhances the sensitivity of PC3 prostate cancer cells to docetaxel (Figure S4C and D) and impairs their self‐renewal ability (Figure S4E and F).